Prime Medicine (NASDAQ:PRME) Upgraded to "Hold" at Wall Street Zen

Key Points

• Prime Medicine has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, indicating a cautious outlook on the stock.
• Despite the upgrade, Weiss Ratings maintains a "sell (e+)" rating on the stock, reflecting mixed analyst sentiment.
• As of Friday, Prime Medicine's shares were trading at $5.33, down 0.9% with a market capitalization of $717.26 million.

Prime Medicine (NASDAQ:PRME - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Prime Medicine in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of "Sell".

Prime Medicine Stock Down 0.9%

Shares of NASDAQ PRME opened at $5.33 on Friday. The company has a market capitalization of $717.26 million, a P/E ratio of -3.42 and a beta of 2.65. Prime Medicine has a 52-week low of $1.11 and a 52-week high of $6.94.

Prime Medicine Company Profile

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.